NCT00990860

Study in Asia of the Combination of TACE With Sorafenib in HCC Patients

START (Study in Asia of the Combination of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib in Hepatocellular Carcinoma (HCC) Patients) Trial

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Taipei Veterans General Hospital, Taiwan · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

TACE possibly plays a significant role in contributing to a subgroup of surviving residual tumor tissue which is characterized by more aggressive biology. This explains the strong scientific rationale for exploring the role of anti-angiogenic therapy such as sorafenib to remedy and strengthen the therapeutic efficacy of TACE to combat liver cancers. Sorafenib plays a prominent auxiliary role by further suppressing the tumor growth and prolonging the time to recurrence and progression. Performing TACE under sorafenib administration may have synergic effect on hepatic tumoral lesions.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	doxorubicin	After identifying the target artery of HCC, doxorubicin will be infused through the target artery of HCC patient with lipiodol emulsion (dependent on the tumor size)
PROCEDURE	TACE (Transcatheter arterial chemoembolization)	TACE (Transcatheter arterial chemoembolization)

Timeline

• Start date: 2009-02-01
• Primary completion: 2011-02-01
• First posted: 2009-10-07
• Last updated: 2011-01-05

Locations

8 sites across 1 country: Taiwan